Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Savara, with a price target of $10.00.

Andrew Fein has given his Buy rating due to a combination of factors that, in his view, significantly improve Savara’s risk‑reward profile. He highlights that the successful resubmission of the Molbreevi BLA using Fujifilm Diosynth as the new manufacturing partner materially lowers regulatory and CMC-related risk, especially after the prior Refusal to File linked to the previous manufacturer. The company’s request for Priority Review, which could bring an approval decision as early as mid-2026, further clarifies the regulatory timeline and supports greater visibility into a potential commercial launch. Fein also points to Savara’s execution on launch preparation, including progress in identifying a large base of aPAP patients ahead of approval, as evidence that the company is operationally prepared to capitalize on approval if granted.
Additionally, Fein views the expanding and better-characterized aPAP patient pool as alleviating prior concerns about the commercial opportunity’s size. New data suggesting a higher prevalence of the disease and a growing number of confirmed patients strengthens confidence that Molbreevi can support a meaningful revenue stream despite aPAP’s rare-disease status. In combination with Savara’s strengthened balance sheet following access to non-dilutive debt financing, he sees the company as well positioned to fund key activities through launch without excessive equity dilution. These elements together underpin his conviction that the Molbreevi program is substantially de-risked on both regulatory and commercial dimensions, justifying a higher price target and a continued Buy rating on SVRA.

In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $11.00 price target.